Fast Five Quiz: Non-Hodgkin Lymphoma (NHL): TP53 in Mantle Cell Lymphoma

Ann S. LaCasce, MD, MMSc


February 08, 2023

Mantle cell lymphoma (MCL) is a relatively rare form of non-Hodgkin lymphoma that is biologically heterogeneous with several subtypes. The clinical course of the disease can be highly variable. Although MCL is aggressive in the majority of patients, some variants of the disease can be indolent.

Risk-stratification models based on biological and clinical features have been developed, and identification of prognostic biomarkers at the time of diagnosis is becoming standard of care.

Although advances in treatment have improved outcomes in MCL, tailored approaches are needed based on the biology of the disease. Studies with novel therapies incorporating prognostic factors and biomarkers of response are under investigation.

How much do you know about prognostic markers of MCL? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.